RT Journal Article
SR Electronic
T1 Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.16.20232835
DO 10.1101/2020.11.16.20232835
A1 Florence WJ Chioh
A1 Siew-Wai Fong
A1 Barnaby E. Young
A1 Kan-Xing Wu
A1 Anthony Siau
A1 Shuba Krishnan
A1 Yi-Hao Chan
A1 Louis LY Teo
A1 Fei Gao
A1 Ru San Tan
A1 Liang Zhong
A1 Angela S. Koh
A1 Seow-Yen Tan
A1 Paul A. Tambyah
A1 Laurent Renia
A1 Lisa FP Ng
A1 David C Lye
A1 Christine Cheung
YR 2020
UL http://medrxiv.org/content/early/2020/11/18/2020.11.16.20232835.abstract
AB The rapid rise of coronavirus disease 2019 patients who suffer from vascular events after their initial recovery is expected to lead to a worldwide shift in disease burden. We aim to investigate the impact of COVID-19 on the pathophysiological state of blood vessels in convalescent patients. Here, convalescent COVID-19 patients with or without preexisting conditions (i.e. hypertension, diabetes, hyperlipidemia) were compared to non-COVID-19 patients with matched cardiovascular risk factors or healthy participants. Convalescent patients had elevated circulating endothelial cells (CECs), and those with underlying cardiovascular risk had more pronounced endothelial activation hallmarks (ICAM1, P-selectin or CX3CL1) expressed by CECs. Multiplex microbead-based immunoassays revealed some levels of cytokine production sustained from acute infection to recovery phase. Several proinflammatory and activated T lymphocyte-associated cytokines correlated positively with CEC measures, implicating cytokine-driven endothelial dysfunction. Finally, the activation markers detected on CECs mapped to the counter receptors (i.e. ITGAL, SELPLG, and CX3CR1) found primarily on CD8+ T cells and natural killer cells, suggesting that activated endothelial cells could be targeted by cytotoxic effector cells. Clinical trials in preventive therapy for post-COVID-19 vascular complications may be needed.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the National Medical Research Council COVID-19 Research Fund (COVID19RF-001 and COVID19RF-060) and COVID-19 (project number H20/04/g1/006) research grants provided to Singapore Immunology Network (SIgN) by the Biomedical Research Council (BMRC), A*STAR. The SIgN flow cytometry, Multiple analyte platforms and Immunomonitoring Service Platform (ISP) were supported a grant (#NRF2017_SISFP09) from the National Research Foundation (NRF), Singapore. The team from Nanyang Technological University Singapore was funded by the Nanyang Assistant Professorship, Academic Research Fund grant (MOE2018-T2-1-042) from the Ministry of Education, Singapore, and an Industrial Alignment Fund Pre-Positioning grant (H18/01/a0/017) from Agency for Science, Technology and Research, Singapore. The team from National Heart Centre Singapore was supported by the National Medical Research Council of Singapore (NMRC/TA/0031/2015, MOH-000153, NMRC/OFIRG/0018/2016, NMRC/BnB/0017/2015, MOH-000358).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Local Ethics Committee of the National Healthcare Group (2012/00917) and Nanyang Technological University Singapore Institutional Review Board (IRB-2020-09-011).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available as they are reported in the manuscript.